Immediate vs. culture-initiated antibiotic therapy in suspected non-severe ventilator-associated pneumonia: a before-after study (DELAVAP).
Antibiotic stewardship
Antibiotic therapy
Critical care
Ventilator-associated pneumonia
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
received:
02
10
2023
accepted:
02
01
2024
medline:
27
2
2024
pubmed:
27
2
2024
entrez:
27
2
2024
Statut:
epublish
Résumé
Ventilator-associated pneumonia (VAP) is the leading nosocomial infection in critical care and is associated with adverse outcomes. When VAP is suspected, starting antibiotic therapy (AT) immediately after pulmonary sampling may expose uninfected patients to unnecessary treatment, whereas waiting for bacteriological confirmation may delay AT in infected patients. As no robust data exist to choose between these strategies, the decision must balance the pre-test diagnostic probability, clinical severity, and risk of antimicrobial resistance. The objective of this study in patients with suspected non-severe VAP was to compare immediate AT started after sampling to conservative AT upon receipt of positive microbiological results. The outcomes were antibiotic sparing, AT suitability, and patient outcomes. This single-center, before-after study included consecutive patients who underwent distal respiratory sampling for a first suspected non-severe VAP episode (no shock requiring vasopressor therapy or severe acute respiratory distress syndrome). AT was started immediately after sampling in 2019 and upon culture positivity in 2022 (conservative strategy). The primary outcome was the number of days alive without AT by day 28. The secondary outcomes were mechanical ventilation duration, day-28 mortality, and AT suitability (active necessary AT or spared AT). The immediate and conservative strategies were applied in 44 and 43 patients, respectively. Conservative and immediate AT were associated with similar days alive without AT (median [interquartile range], 18.0 [0-21.0] vs. 16.0 [0-20.0], p = 0.50) and without broad-spectrum AT (p = 0.53) by day 28. AT was more often suitable in the conservative group (88.4% vs. 63.6%, p = 0.01), in which 27.9% of patients received no AT at all. No significant differences were found for mechanical ventilation duration (median [95%CI], 9.0 [6-19] vs. 9.0 [6-24] days, p = 0.65) or day-28 mortality (hazard ratio [95%CI], 0.85 [0.4-2.0], p = 0.71). In patients with suspected non-severe VAP, waiting for microbiological confirmation was not associated with antibiotic sparing, compared to immediate AT. This result may be ascribable to low statistical power. AT suitability was better with the conservative strategy. None of the safety outcomes differed between groups. These findings would seem to allow a large, randomized trial comparing immediate and conservative AT strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Ventilator-associated pneumonia (VAP) is the leading nosocomial infection in critical care and is associated with adverse outcomes. When VAP is suspected, starting antibiotic therapy (AT) immediately after pulmonary sampling may expose uninfected patients to unnecessary treatment, whereas waiting for bacteriological confirmation may delay AT in infected patients. As no robust data exist to choose between these strategies, the decision must balance the pre-test diagnostic probability, clinical severity, and risk of antimicrobial resistance. The objective of this study in patients with suspected non-severe VAP was to compare immediate AT started after sampling to conservative AT upon receipt of positive microbiological results. The outcomes were antibiotic sparing, AT suitability, and patient outcomes.
METHODS
METHODS
This single-center, before-after study included consecutive patients who underwent distal respiratory sampling for a first suspected non-severe VAP episode (no shock requiring vasopressor therapy or severe acute respiratory distress syndrome). AT was started immediately after sampling in 2019 and upon culture positivity in 2022 (conservative strategy). The primary outcome was the number of days alive without AT by day 28. The secondary outcomes were mechanical ventilation duration, day-28 mortality, and AT suitability (active necessary AT or spared AT).
RESULTS
RESULTS
The immediate and conservative strategies were applied in 44 and 43 patients, respectively. Conservative and immediate AT were associated with similar days alive without AT (median [interquartile range], 18.0 [0-21.0] vs. 16.0 [0-20.0], p = 0.50) and without broad-spectrum AT (p = 0.53) by day 28. AT was more often suitable in the conservative group (88.4% vs. 63.6%, p = 0.01), in which 27.9% of patients received no AT at all. No significant differences were found for mechanical ventilation duration (median [95%CI], 9.0 [6-19] vs. 9.0 [6-24] days, p = 0.65) or day-28 mortality (hazard ratio [95%CI], 0.85 [0.4-2.0], p = 0.71).
CONCLUSION
CONCLUSIONS
In patients with suspected non-severe VAP, waiting for microbiological confirmation was not associated with antibiotic sparing, compared to immediate AT. This result may be ascribable to low statistical power. AT suitability was better with the conservative strategy. None of the safety outcomes differed between groups. These findings would seem to allow a large, randomized trial comparing immediate and conservative AT strategies.
Identifiants
pubmed: 38411756
doi: 10.1186/s13613-024-01243-z
pii: 10.1186/s13613-024-01243-z
doi:
Types de publication
Journal Article
Langues
eng
Pagination
33Informations de copyright
© 2024. The Author(s).
Références
Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36:1999–2006.
pubmed: 27287765
doi: 10.1007/s10096-016-2703-z
Branch-Elliman W, Wright SB, Howell MD. Determining the ideal strategy for ventilator-associated pneumonia prevention cost-benefit analysis. Am J Respir Crit Care Med. 2015;192:57–63.
pubmed: 25871807
doi: 10.1164/rccm.201412-2316OC
Bekaert M, Timsit J-F, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184:1133–9.
pubmed: 21852541
doi: 10.1164/rccm.201105-0867OC
Klompas M. Does this patient have ventilator-associated pneumonia? JAMA. 2007;297:1583–93.
pubmed: 17426278
doi: 10.1001/jama.297.14.1583
Guidry CA, Beyene RT, Watson CM, Sawyer RG, Chollet-Hinton L, Simpson SQ, et al. Trial of antibiotic restraint in presumed pneumonia: A Surgical Infection Society multicenter pilot. J Trauma Acute Care Surg. 2023;94:232.
pubmed: 36534474
doi: 10.1097/TA.0000000000003839
Lucet JC, Chevret S, Decré D, Vanjak D, Macrez A, Bédos JP, et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis Off Publ Infect Dis Soc Am. 1996;22:430–6.
doi: 10.1093/clinids/22.3.430
D’Agata EM, Venkataraman L, DeGirolami P, Burke P, Eliopoulos GM, Karchmer AW, et al. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med. 1999;27:1090–5.
pubmed: 10397210
doi: 10.1097/00003246-199906000-00026
Richard P, Delangle MH, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;32:162–6.
doi: 10.1086/317551
Le Terrier C, Vinetti M, Bonjean P, Richard R, Jarrige B, Pons B, et al. Impact of a restrictive antibiotic policy on the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an endemic region: a before-and-after, propensity-matched cohort study in a Caribbean intensive care unit. Crit Care Lond Engl. 2021;25:261.
doi: 10.1186/s13054-021-03660-z
Hranjec T, Rosenberger LH, Swenson B, Metzger R, Flohr TR, Politano AD, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis. 2012;12:774–80.
pubmed: 22951600
pmcid: 3462590
doi: 10.1016/S1473-3099(12)70151-2
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 Countries. JAMA. 2016;315:788–800.
pubmed: 26903337
doi: 10.1001/jama.2016.0291
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49: e1063.
pubmed: 34605781
doi: 10.1097/CCM.0000000000005337
Karakuzu Z, Iscimen R, Akalin H, Girgin NK, Kahveci F, Sinirtas M. Prognostic risk factors in ventilator-associated pneumonia. Med Sci Monit Int Med J Exp Clin Res. 2018;24:1321–8.
Martin-Loeches I, Torres A, Povoa P, Zampieri FG, Salluh J, Nseir S, et al. The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. Intensive Care Med. 2019;45:1753–62.
pubmed: 31620836
doi: 10.1007/s00134-019-05797-6
Zampieri FG, Póvoa P, Salluh JI, Rodriguez A, Valade S, Andrade Gomes J, et al. Lower respiratory tract infection and short-term outcome in patients with acute respiratory distress syndrome. J Intensive Care Med. 2020;35:588–94.
pubmed: 29699468
doi: 10.1177/0885066618772498
Moreau A-S, Martin-Loeches I, Povoa P, Salluh J, Rodriguez A, Thille AW, et al. Impact of immunosuppression on incidence, aetiology and outcome of ventilator-associated lower respiratory tract infections. Eur Respir J. 2018;51:1701656.
pubmed: 29439020
doi: 10.1183/13993003.01656-2017
Vacheron C-H, Lepape A, Savey A, Machut A, Timsit JF, Vanhems P, et al. Increased incidence of ventilator-acquired pneumonia in coronavirus disease 2019 patients: a multicentric Cohort study. Crit Care Med. 2022;50:449–59.
pubmed: 34637422
doi: 10.1097/CCM.0000000000005297
Kalanuria AA, Zai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014;18:208.
pubmed: 25029020
pmcid: 4056625
doi: 10.1186/cc13775
Leone M, Bouadma L, Bouhemad B, Brissaud O, Dauger S, Gibot S, et al. Pneumonies associées aux soins de réanimation* RFE commune SFAR–SRLF. Médecine Intensive Réanimation. 2019;28:261–81.
doi: 10.3166/rea-2019-0106
Berton DC, Kalil AC, Teixeira PJZ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD006482.pub4 .
doi: 10.1002/14651858.CD006482.pub4
pubmed: 25354013
SPF. Surveillance de la consommation d’antibiotiques et des résistances bactériennes en établissement de santé. Mission Spares. Résultats 2021. https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-associees-aux-soins-et-resistanceaux-antibiotiques/resistance-aux-antibiotiques/documents/rapport-synthese/surveillance-de-la-consommation-dantibiotiques-et-des-resistances-bacteriennes-en-etablissement-de-sante-mission-spares.-resultats-2021
O’Horo JC, Thompson D, Safdar N. Is the gram stain useful in the microbiologic diagnosis of VAP? A Meta-analysis. Clin Infect Dis. 2012;55:551–61.
pubmed: 22677711
doi: 10.1093/cid/cis512
Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28:521–47.
Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med. 1981;9:591–7.
pubmed: 7261642
doi: 10.1097/00003246-198108000-00008
Chastre J, Wolff M, Fagon J-Y, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–98.
pubmed: 14625336
doi: 10.1001/jama.290.19.2588
Defined Daily Dose (DDD). https://www.whocc.no/ddd/definition_and_general_considera/
Stanić Benić M, Milanič R, Monnier AA, Gyssens IC, Adriaenssens N, Versporten A, et al. Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. J Antimicrob Chemother. 2018;2018(73):vi50-8.
doi: 10.1093/jac/dky118
Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262–8.
pubmed: 12114368
doi: 10.1378/chest.122.1.262
Clec’h C, Timsit J-F, Lassence AD, Azoulay E, Alberti C, Garrouste-Orgeas M, et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med. 2004;2004(30):1327–33.
doi: 10.1007/s00134-004-2292-7
Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med. 2001;27:355–62.
pubmed: 11396279
doi: 10.1007/s001340000640
Leroy O, Meybeck A, d’Escrivan T, Devos P, Kipnis E, Georges H. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med. 2003;29:2170–3.
pubmed: 13680112
doi: 10.1007/s00134-003-1990-x
Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically Ill patient. Am J Respir Crit Care Med. 1999;159:1249–56.
pubmed: 10194173
doi: 10.1164/ajrccm.159.4.9807050
Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, El-Ebiary M, Carrillo A, Ruiz J, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated Pneumonia: a pilot study. Am J Respir Crit Care Med. 1998;157:371–6.
pubmed: 9476845
doi: 10.1164/ajrccm.157.2.97-02039
Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997;111:676–85.
pubmed: 9118708
doi: 10.1378/chest.111.3.676
Rello J, Gallego M, Mariscal D, Soñora R, Valles J. The value of routine microbial investigation in ventilator-associated Pneumonia. Am J Respir Crit Care Med. 1997;156:196–200.
pubmed: 9230747
doi: 10.1164/ajrccm.156.1.9607030
Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998;113:412–20.
pubmed: 9498961
doi: 10.1378/chest.113.2.412
Timsit JF, Cheval C, Gachot B, Bruneel F, Wolff M, Carlet J, et al. Usefulness of a strategy based on bronchoscopy with direct examination of bronchoalveolar lavage fluid in the initial antibiotic therapy of suspected ventilator-associated pneumonia. Intensive Care Med. 2001;27:640–7.
pubmed: 11398689
doi: 10.1007/s001340000840
Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23:91–100.
pubmed: 18359426
doi: 10.1016/j.jcrc.2007.08.007
Fernando SM, Tran A, Cheng W, Klompas M, Kyeremanteng K, Mehta S, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis. Intensive Care Med. 2020;46:1170–9.
pubmed: 32306086
pmcid: 7223448
doi: 10.1007/s00134-020-06036-z
Nora D, Póvoa P. Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies. Ann Transl Med. 2017;5:450.
pubmed: 29264367
pmcid: 5721221
doi: 10.21037/atm.2017.09.16
Hassinger TE, Sawyer RG. Should we immediately start antibiotics in every patient with a clinical suspicion of HAP/VAP? Semin Respir Crit Care Med. 2017;38:245–52.
pubmed: 28578549
doi: 10.1055/s-0037-1602581
Denny KJ, De Wale J, Laupland KB, Harris PNA, Lipman J. When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit. Clin Microbiol Infect. 2020;26:35–40.
pubmed: 31306790
doi: 10.1016/j.cmi.2019.07.007
Prescott HC, Iwashyna TJ. Improving sepsis treatment by embracing diagnostic uncertainty. Ann Am Thorac Soc. 2019;16:426–9.
pubmed: 30883190
pmcid: 6441693
doi: 10.1513/AnnalsATS.201809-646PS
Sterling SA, Miller WR, Pryor J, Puskarich MA, Jones AE. The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis. Crit Care Med. 2015;43:1907–15.
pubmed: 26121073
pmcid: 4597314
doi: 10.1097/CCM.0000000000001142
Bisarya R, Song X, Salle J, Liu M, Patel A, Simpson SQ. Antibiotic timing and progression to septic shock among patients in the ED with suspected infection. Chest. 2022;161:112–20.
pubmed: 34186038
doi: 10.1016/j.chest.2021.06.029
Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017;376:2235–44.
pubmed: 28528569
pmcid: 5538258
doi: 10.1056/NEJMoa1703058
Alam N, Oskam E, Stassen PM, van Exter P, van de Ven PM, Haak HR, et al. Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial. Lancet Respir Med. 2018;6:40–50.
pubmed: 29196046
doi: 10.1016/S2213-2600(17)30469-1
Chang R, Elhusseiny KM, Yeh Y-C, Sun W-Z. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes-A systematic review and meta-analysis. PLoS ONE. 2021;16: e0246318.
pubmed: 33571301
pmcid: 7877631
doi: 10.1371/journal.pone.0246318
Blonz G, Kouatchet A, Chudeau N, Pontis E, Lorber J, Lemeur A, et al. Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region. Crit Care. 2021;25:72.
pubmed: 33602296
pmcid: 7891465
doi: 10.1186/s13054-021-03493-w
Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;47:188–98.
pubmed: 33388794
pmcid: 7778569
doi: 10.1007/s00134-020-06323-9
Bambi S, Iozzo P, Lucchini A. New issues in nursing management during the COVID-19 pandemic in Italy. Am J Crit Care. 2020;29:e92–3.
pubmed: 32467964
doi: 10.4037/ajcc2020937
Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: a systematic review and meta-analysis. Front Public Health. 2022;10: 873596.
pubmed: 36091533
pmcid: 9459165
doi: 10.3389/fpubh.2022.873596
Yoshimura J, Yamakawa K, Ohta Y, Nakamura K, Hashimoto H, Kawada M, et al. Effect of gram stain-guided initial antibiotic therapy on clinical response in patients with ventilator-associated Pneumonia: the GRACE-VAP randomized clinical trial. JAMA Netw Open. 2022;5: e226136.
pubmed: 35394515
pmcid: 8994124
doi: 10.1001/jamanetworkopen.2022.6136